LZIC Inhibitors
Chemical inhibitors of LZIC function through various mechanisms by influencing the cellular pathways and processes with which this protein is associated. Staurosporine, a known inhibitor of protein kinase C (PKC), disrupts the Wnt/β-catenin pathway, crucial for cellular signaling and gene expression regulation. Since LZIC is associated with this pathway, Staurosporine's inhibition of PKC leads to a downstream effect on LZIC, impairing its functional role in the pathway. Rapamycin targets the mTOR pathway, integral for cell growth and cycle progression. Given LZIC's involvement in cell cycle regulation, the inhibition of mTOR by Rapamycin indirectly hinders LZIC's role in these processes. Similarly, LY 294002, by inhibiting PI3K, and PD 98059, by targeting MEK in the MAPK/ERK pathway, indirectly impact LZIC's function.
Additional chemicals, such as SB 203580 and SP600125, inhibit specific kinases like p38 MAPK and JNK, respectively. These kinases are involved in stress response and apoptosis, processes in which LZIC plays a part. Therefore, the inhibition of these kinases can indirectly reduce LZIC's effectiveness in regulating these cellular responses. U0126, another MEK inhibitor, further emphasizes the role of MAPK/ERK pathway inhibition in indirectly influencing LZIC function. Bortezomib's role in inhibiting proteasome activity impacts the degradation of proteins involved in the cell cycle, thereby indirectly inhibiting LZIC's function in these processes. Thapsigargin and Nutlin-3, by disrupting calcium signaling and the p53-MDM2 interaction respectively, also indirectly impair LZIC's role in cellular regulation. Lastly, HDAC inhibitors like Trichostatin A and Suberoylanilide Hydroxamic Acid, by altering gene expression patterns, have the potential to indirectly inhibit LZIC's function in the regulation of the cell cycle. These diverse chemicals, though not directly targeting LZIC, exert their influence on various cellular pathways and processes, resulting in the inhibition of LZIC's functional role within these contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinase C (PKC), a key regulator in the Wnt/β-catenin pathway. LZIC is associated with the Wnt/β-catenin signaling pathway. By inhibiting PKC, Staurosporine disrupts the pathway, leading to reduced LZIC protein function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cell cycle progression and growth. LZIC is involved in cell cycle regulation. Inhibition of mTOR by Rapamycin can disrupt cell cycle progression, indirectly inhibiting LZIC function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor. PI3K/Akt signaling is involved in various cellular processes including cell growth. As LZIC is associated with cell cycle control, inhibiting PI3K can impede cell growth pathways, indirectly inhibiting LZIC. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 inhibits MEK, which is part of the MAPK/ERK pathway. LZIC is implicated in cell cycle regulation. By inhibiting MEK, PD 98059 disrupts the MAPK/ERK pathway, indirectly affecting LZIC's role in cell cycle control. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. The p38 MAPK pathway plays a role in stress response and apoptosis. LZIC, being involved in cell cycle regulation, can be indirectly inhibited by SB 203580 through disruption of p38 MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in stress response and apoptosis pathways. LZIC, associated with cell cycle regulation, can be indirectly inhibited by SP600125 through disruption of JNK signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components of the MAPK/ERK pathway. As LZIC is involved in cell cycle regulation, inhibiting MEK1/2 disrupts this pathway, indirectly affecting LZIC's regulatory function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits proteasome activity. The ubiquitin-proteasome pathway is essential for protein degradation, including those involved in cell cycle. LZIC, being associated with cell cycle regulation, can be indirectly inhibited by Bortezomib through proteasome inhibition. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Calcium signaling is vital for various cellular processes. Inhibition of calcium signaling by Thapsigargin can indirectly affect LZIC function in cell cycle regulation. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2. Since LZIC is associated with cell cycle control, and p53 plays a key role in this process, inhibiting the p53-MDM2 interaction can indirectly inhibit LZIC by altering cell cycle regulation. | ||||||